959761-81-0

Basic information

• Product Name: methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate p-toluenesulfonic acid salt
• Synonyms: methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate p-toluenesulfonic acid salt
• CAS NO: 959761-81-0
• Molecular Weight: 711.839
• Mol File: 959761-81-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate p-toluenesulfonic acid salt(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate p-toluenesulfonic acid salt(959761-81-0)
• EPA Substance Registry System: methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate p-toluenesulfonic acid salt(959761-81-0)

Safety Data

• Hazardous Substances Data: 959761-81-0(Hazardous Substances Data)

Upstream product

• 656247-17-5 nintedanib 
• 104-15-4 toluene-4-sulfonic acid 

Relevant articles and documents

CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO} PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF

The present solution relates to crystalline modifications of methyl (3Z)-3-{[(4-{methyl[(4- methylpiperazin-l-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-lH-indole- 6-carboxylate salts of Formula I, wherein HX represents at least one acid component, preferably methanesulfonic acid, p-toluenesulphonic acid, L-tartaric acid, maleic acid, acetic acid and phosphoric acid. Another solution also relates to the processes for the preparation thereof as well as said use thereof in phamaceutically acceptable compositions. Use of said crystalline forms of intedanib and manufactured salts in the preparation of methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-l- yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-lH-indole-6-carboxylate in the form of any phamaceutically acceptable salt thereof is also object of this invention.